Issue

Vol. 63 No. 1: Issue 1

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Association between circulating transforming growth factor-β1 level and polymorphisms in systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis

https://doi.org/10.14715/cmb/2017.63.1.11
Y. H. Lee
Rheumatology, Korea University Medical Center.
S-C. Bae
Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea

Corresponding Author(s) : Y. H. Lee

lyhcgh@korea.ac.kr

Cellular and Molecular Biology, Vol. 63 No. 1: Issue 1

Abstract

This study systemically reviewed evidence regarding the relationship between circulating blood transforming growth factor-β1 (TGF-β1) levels and systemic lupus erythematous (SLE) and rheumatoid arthritis (RA), and associations between TGF-β1 polymorphisms and susceptibility to SLE and RA.  We conducted a meta-analysis on the serum/plasma TGF-β1 levels in SLE and RA patients and healthy controls, and the associations between TGF-β1 +869 T/C, +915 C/G, and -509 T/C polymorphisms and SLE or RA risk. Twenty-eight studies were considered in this meta-analysis. Circulating TGF-β1 levels were significantly lower in the SLE group than in controls (SMD = -1.164, 95% CI = -2.257 – -0.070, P = 0.037). Serum/plasma TGF-β1 levels were not significantly different between RA and control groups (SMD = 0.699, 95% CI = -0.379 – 1.717, p = 0.211). No association between TGF-β1 +869 T/C polymorphism and SLE was found. However, meta-analysis showed an association between the TGF-β1 +869 T allele and RA in all subjects (OR = 1.282, 95% CI = 1.118–1.470, P = 3.8 x 10-4). Analysis after stratification by ethnicity indicated that the T allele was significantly associated with RA in Asians and Arabs (OR = 1.429, 95% CI = 1.179–1.733, P = 2.9 x 10-4; OR = 1.352, 95% CI = 1.097–1.668, P = 0.005), but not Europeans. However, no association was found between TGF-β1 +915 G/C or -509 C/T polymorphisms and RA or SLE. Meta-analysis revealed a significantly lower circulating TGF-β1 level in SLE patients, and a significant association between TGF-β1 +869 T/C polymorphism and RA development.

Keywords

TGF-β1 level Polymorphism SLE RA.
Lee, Y. H., & Bae, S.-C. (2017). Association between circulating transforming growth factor-β1 level and polymorphisms in systemic lupus erythematosus and rheumatoid arthritis: A meta-analysis. Cellular and Molecular Biology, 63(1), 53–59. https://doi.org/10.14715/cmb/2017.63.1.11
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Ruiz-Irastorza G, Khamashta MA, Castellino G,Hughes GR. Systemic lupus erythematosus. Lancet 2001; 357: 1027-1032.
  2. Mellado M, Martí­nez-Muñoz L, Cascio G, Lucas P, Pablos JL,Rodrí­guez-Frade JM. T cell migration in rheumatoid arthritis. Frontiers in immunology 2015; 6.
  3. Letterio JJ,Roberts AB. Regulation of immune responses by TGF-β*. Annual review of immunology 1998; 16: 137-161.
  4. Aoki CA, Borchers AT, Li M, et al. Transforming growth factor β (TGF-β) and autoimmunity. Autoimmunity reviews 2005; 4: 450-459.
  5. Ohtsuka K, Gray J, Stimmler M,Horwitz D. The relationship between defects in lymphocyte production of transforming growth factor-β1 in systemic lupus erythematosus and disease activity or severity. Lupus 1999; 8: 90-94.
  6. Chu C-Q, Field M, Abney E, et al. Transforming growth factor"β1 in rheumatoid synovial membrane and cartilage pannus junction. Clinical & Experimental Immunology 1991; 86: 380-386.
  7. Zhang L, Yan J-w, Wang Y-X, et al. Association of TGF-β1+ 869C/T promoter polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Molecular biology reports 2013; 40: 4811-4817.
  8. Yamada Y, Miyauchi A, Goto J, et al. Association of a Polymorphism of the Transforming Growth Factor"β1 Gene with Genetic Susceptibility to Osteoporosis in Postmenopausal Japanese Women. Journal of Bone and Mineral Research 1998; 13: 1569-1576.
  9. Awad M, El-Gamel A, Hasleton P, Turner D, Sinnott P,Hutchinson I. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998; 66: 1014-1020.
  10. Grainger DJ, Heathcote K, Chiano M, et al. Genetic control of the circulating concentration of transforming growth factor type β1. Human molecular genetics 1999; 8: 93-97.
  11. Sayed SK, Galal SH, Herdan OM,Mahran AM. Single nucleotide polymorphism T869C of transforming growth factor-beta 1 gene and systemic lupus erythematosus: association with disease susceptibility and lupus nephritis. Egypt J Immunol 2014; 21: 9-21.
  12. Antiga E, Del Bianco E, Difonzo E, Fabbri P,Caproni M. Serum levels of the regulatory cytokines transforming growth factor-beta and interleukin-10 are reduced in patients with discoid lupus erythematosus. Lupus 2011; 20: 556-560.
  13. Becker-Merok A, Eilertsen Gí˜,Nossent JC. Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease. The Journal of rheumatology 2010; 37: 2039-2045.
  14. Hammad AM, Youssef HM,El-Arman MM. Transforming growth factor beta 1 in children with systemic lupus erythematosus: a possible relation with clinical presentation of lupus nephritis. Lupus 2006; 15: 608-612.
  15. Lu LY, Cheng HH, Sung PK, Yeh JJ, Shiue YL,Chen A. Single-nucleotide polymorphisms of transforming growth factor-beta1 gene in Taiwanese patients with systemic lupus erythematosus. J Microbiol Immunol Infect 2004; 37: 145-152.
  16. Bennett AL, Chao CC, Hu S, et al. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 1997; 17: 160-166.
  17. Harman H, Tekeoglu I, Gurol G, et al. Comparison of fetuin-A and transforming growth factor beta 1 levels in patients with spondyloarthropathies and rheumatoid arthritis. Int J Rheum Dis 2016.
  18. Mieliauskaite D, Venalis P, Dumalakiene I, Venalis A,Distler J. Relationship between serum levels of TGF-beta1 and clinical parameters in patients with rheumatoid arthritis and Sjogren's syndrome secondary to rheumatoid arthritis. Autoimmunity 2009; 42: 356-358.
  19. Rico MC, Manns JM, Driban JB, Uknis AB, Kunapuli SP,Cadena RAD. Thrombospondin-1 and transforming growth factor beta are pro-inflammatory molecules in rheumatoid arthritis. Translational Research 2008; 152: 95-98.
  20. Eriksson P, Andersson C, Ekerfelt C, Ernerudh J,Skogh T. Relationship between serum levels of IL-18 and IgG1 in patients with primary Sjogren's syndrome, rheumatoid arthritis and healthy controls. Clin Exp Immunol 2004; 137: 617-620.
  21. Rezaei A, Ziaee V, Sharabian FT, et al. Lack of association between interleukin-10, transforming growth factor-beta gene polymorphisms and juvenile-onset systemic lupus erythematosus. Clin Rheumatol 2015; 34: 1059-1064.
  22. Wang B, Morinobu A, Kanagawa S, et al. Transforming growth factor beta 1 gene polymorphism in Japanese patients with systemic lupus erythematosus. Kobe J Med Sci 2007; 53: 15-23.
  23. Guarnizo"Zuccardi P, Lopez Y, Giraldo M, et al. Cytokine gene polymorphisms in Colombian patients with systemic lupus erythematosus. Tissue antigens 2007; 70: 376-382.
  24. Caserta TM, Knisley AA, Tan FK, Arnett FC,Brown TL. Genotypic analysis of the TGF beta-509 allele in patients with systemic lupus erythematosus and Sjogren's syndrome. Ann Genet 2004; 47: 359-363.
  25. Schotte H, Willeke P, Rust S, et al. The transforming growth factor-beta1 gene polymorphism (G915C) is not associated with systemic lupus erythematosus. Lupus 2003; 12: 86-92.
  26. Saad MN, Mabrouk MS, Eldeib AM,Shaker OG. Genetic Case-Control Study for Eight Polymorphisms Associated with Rheumatoid Arthritis. PLoS One 2015; 10: e0131960.
  27. Hussein YM, Mohamed RH, El-Shahawy EE,Alzahrani SS. Interaction between TGF-beta1 (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis. Gene 2014; 536: 393-397.
  28. Zhou TB, Zhao HL, Fang SL,Drummen GP. Association of transforming growth factor-beta1 T869C, G915C, and C509T gene polymorphisms with rheumatoid arthritis risk. J Recept Signal Transduct Res 2014; 34: 469-475.
  29. Lee YH, Woo JH, Choi SJ, Ji JD,Song GG. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus: An International Journal 2010; 19: 703-710.
  30. Lee YH, Woo JH, Choi SJ, Ji JD,Song GG. Association of programmed cell death 1 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus: An International Journal 2009; 18: 9-15.
  31. Lee YH, Woo JH, Choi SJ, Ji JD,Song GG. Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Molecular biology reports 2010; 37: 227-234.
  32. Moher D, Liberati A, Tetzlaff J, Altman DG,Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
  33. Hozo SP, Djulbegovic B,Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC medical research methodology 2005; 5: 13.
  34. Ridout KK, Ridout SJ, Price LH, Sen S,Tyrka AR. Depression and telomere length: A meta-analysis. Journal of affective disorders 2016; 191: 237-247.
  35. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, New Jersey: L. Erlbaum, 1988.
  36. Egger M, Smith GD,Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537.
  37. DerSimonian R,Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
  38. Higgins JP,Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
  39. Egger M, Davey Smith G, Schneider M,Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
  40. Taylor A, Verhagen J, Blaser K, Akdis M,Akdis CA. Mechanisms of immune suppression by interleukin"10 and transforming growth factor"β: the role of T regulatory cells. Immunology 2006; 117: 433-442.
  41. Gualtierotti R, Biggioggero M, Penatti A,Meroni P. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmunity reviews 2010; 10: 3-7.
  42. Filippi CM, Juedes AE, Oldham JE, et al. Transforming Growth Factor-β Suppresses the Activation of CD8+ T-Cells When Naí¯ve but Promotes Their Survival and Function Once Antigen Experienced A Two-Faced Impact on Autoimmunity. Diabetes 2008; 57: 2684-2692.
  43. Zhou T-B, Zhao H-L, Fang S-L,Drummen GP. Association of transforming growth factor-β1 T869C, G915C, and C509T gene polymorphisms with rheumatoid arthritis risk. Journal of Receptors and Signal Transduction 2014; 34: 469-475.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 804 Download : 328